Home Companies Catalysts Deep Dives
Gardasil 9 human papillomavirus 9-valent vaccine APPROVED
Drug Profile
ModalityVaccine
RouteIM
Therapy AreaInfectious Disease
Launch2014-12-10
US LOE2028-01-01
Peak Sales Est$11000M
Formulations[{"id":"gardasil-im","route":"IM","setting":"CLINIC","frequency":"2-3 doses","is_primary":true}]
Companies
MRK (ORIGINATOR)100%
Mechanism: HPV vaccine (VLP)
Expert: Virus-like particle vaccine inducing neutralizing antibodies against HPV
Everyday: Trains immune system to prevent HPV infection
Targets: []
Revenue History
PeriodRevenue ($M)
2023$8,886M
2024$8,583M
2025$5,200M
Q1 2024$2,249M
Q2 2024$2,478M
Q3 2024$2,306M
Q4 2024$1,550M
Q1 2025$1,330M
Q2 2025$1,250M
Q3 2025$1,320M
Q4 2025$1,300M
Programs (1)
IndicationStageKey StudyRegional Status
HPV PreventionAPPROVEDV503-001[{"stage":"APPROVED","region":"US","approval_date":"2014-12-10"}]
Upcoming Catalysts (1)
Gardasil - China Demand Update 2026
Notes
Leading HPV vaccine. Strong demand in China. Adult vaccination expansion opportunity.
Data from Supabase · Updated 2026-03-24